Rottendorf Pharma GmbH, Ostenfelder Straße 51-61, 59320 Ennigerloh, Germany.
Institute of Pharmaceutical Technology and Biopharmacy, University of Muenster, Corrensstraße 48, 48149 Münster, Germany.
Eur J Pharm Biopharm. 2019 Jan;134:77-87. doi: 10.1016/j.ejpb.2018.11.011. Epub 2018 Nov 14.
Incorporating poorly soluble drugs into polymeric nanoparticles is a widely investigated approach to improve their biopharmaceutical performance. Poly(DL-lactide-co-glycolide) (PLGA) nanoparticle formulations have previously been tested and recommended as drug carriers for peroral administration of poorly soluble porphyrin derivatives intended for photodynamical therapy. Based on those PLGA formulations the present study investigates conventional techniques like fluid bed granulation and tableting for conversion of such polymeric nanoparticle suspensions into solid dosage forms. Analytical methods like asymmetrical flow field-flow fractionation (AF4) and photon correlation spectroscopy (PCS) were used to assess changes of the nanoparticle properties during processing and the recovery after redispersion of the solid dosage forms. Preliminary experiments were conducted to demonstrate the feasibility of the granulation and tableting strategy. Afterwards, design of experiments (DoE) was used to determine formulation and process parameters with critical influence on several properties of the solid forms, in particular the recovery of nanoparticles during dissolution testing. Fluid bed granulation with aqueous PLGA nanoparticle suspensions and soluble carriers was shown to be a simple and high yield process for drying of the nanoparticles. The nanoparticle concentration of the granulation suspension and the ratio of the spraying rate and the atomization air pressure were critical for the physicochemical characteristics of the granules like density and particle size distribution (PSD) as well as for the redispersibility to nanoparticle suspensions of original properties. The granules were compressed to tablets without impairing the nanoparticle diameter and the recovery when an adequate level of filler and low compression forces were used.
将难溶性药物包埋于聚合物纳米粒中是提高其生物药剂学性能的一种广泛研究的方法。聚(DL-丙交酯-共-乙交酯)(PLGA)纳米粒制剂以前已经过测试并被推荐作为用于口服给予用于光动力疗法的难溶性卟啉衍生物的药物载体。基于这些 PLGA 制剂,本研究考察了常规技术,如流化床造粒和压片,以将此类聚合物纳米粒混悬液转化为固体剂型。分析方法,如不对称流场流分离(AF4)和光子相关光谱(PCS),用于评估加工过程中纳米粒性质的变化以及固体剂型重新分散后的恢复情况。进行了初步实验以证明造粒和压片策略的可行性。随后,使用设计实验(DoE)来确定对固体形式的几个性质具有关键影响的配方和工艺参数,特别是在溶解测试中纳米粒的恢复。使用水性 PLGA 纳米粒混悬液和可溶性载体进行流化床造粒是一种简单且高产率的干燥纳米粒的方法。造粒悬浮液中的纳米粒浓度以及喷雾速率与雾化空气压力之比对于颗粒的物理化学特性(如密度和粒径分布(PSD))以及对于以原始性质重新分散为纳米粒混悬液的能力至关重要。当使用足够水平的填充剂和低压缩力时,颗粒可以被压缩成片剂而不会损害纳米粒直径和恢复性。